Zobrazeno 1 - 10
of 72
pro vyhledávání: '"JE Megías Vericat"'
Autor:
T Palanques Pastor, Giraldo Rodríguez, Isabel Cano, Pacheco Martínez, J.L. Poveda Andrés, J Cornago Navascués, M Arnan Sangerman, JL López Lorenzo, JE Megías Vericat, P Montestinos
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance SARS-CoV-2 infection can impact the survival of patients with acute myeloid leukaemia (AML) but there is little published evidence in AML Aim and objectives To analyse the clinical futures and outcome of SARS-CoV-2 infection
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cf0c6aef7243af17865f92f5108904d9
https://doi.org/10.1136/ejhpharm-2021-eahpconf.119
https://doi.org/10.1136/ejhpharm-2021-eahpconf.119
Autor:
F. Gómez Muñoz, E López Briz, J. Ramos Ruiz, J. Martinez Rodrigo, JE Megías Vericat, R. García Marcos, J.L. Poveda Andrés
Publikováno v:
Radiologia
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
OBJECTIVES: To compare the effectiveness, survival and cost in patients with unresectable hepatic cell carcinoma (HCC) treated with trans-arterial chemoembolization using doxorubicin-eluting beads (DEB-TACE) versus conventional TACE (cTACE) in clinic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e249f76d33147f0d1c9a9c8ac767ef2
https://doi.org/10.1016/j.rxeng.2015.09.004
https://doi.org/10.1016/j.rxeng.2015.09.004
Autor:
E López Briz, J. Martinez Rodrigo, R. García Marcos, J. Ramos Ruiz, J.L. Poveda Andrés, JE Megías Vericat, F. Gómez Muñoz
Publikováno v:
Radiología. 57:496-504
Resumen Objetivo Comparar la efectividad, supervivencia y coste de la quimioembolizacion transarterial con particulas liberadoras de doxorrubicina (DEB-TACE) y la quimioembolizacion convencional (cTACE) en pacientes con carcinoma hepatocelular (CHC)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::10dc27ea6440adbe0f7c2c83b7acdf2e
https://doi.org/10.1016/j.rx.2015.01.008
https://doi.org/10.1016/j.rx.2015.01.008
Autor:
A Ferrada Gascó, JE Megías Vericat, MJ Company Albir, AA García Robles, C Favieres Puigcerver, O Ballesta López, MJ Fernández Megía, FC Pérez Miralles, JL Poveda Andrés, B Casanova Estruch
Publikováno v:
Clinical pharmacy.
Background Progressive multifocal leukoencephalopathy(PML) is caused by JC virus (JCV) and has severe consequences for the central nervous system. PML is an opportunistic infection, affecting HIV positive patients. There is no curative treatment, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c8d26969327d36c0e2b3c940389d088a
https://doi.org/10.1136/ejhpharm-2017-000640.69
https://doi.org/10.1136/ejhpharm-2017-000640.69
Autor:
AA García Robles, MJ Company Albir, JE Megías Vericat, A Ferrada Gascó, MJ Fernández Megía, FC Pérez Miralles, C Alcalá Vicente, I Boscá Blasco, JL Poveda Andrés, B Casanova Estruch
Publikováno v:
Clinical pharmacy.
Background Inaccessibility of inflammation compartmentalised to the CNS may underlie the lack of effectiveness of immunomodulatory treatments in progressive multiple sclerosis (PMS), turning its treatment into a challenge for researches. Intrathecal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ac8d7b62f2279fecdd0251f7fb830158
https://doi.org/10.1136/ejhpharm-2017-000640.219
https://doi.org/10.1136/ejhpharm-2017-000640.219
Autor:
Salvador F. Aliño, María José Herrero, Virginia Bosó, David Martínez-Cuadrón, JE Megías Vericat, Miguel-Angel Sanz, Luis Rojas, José Luis Poveda, Pau Montesinos, Federico Moscardó
Publikováno v:
European Journal of Hospital Pharmacy. 23:A187-A187
Background NADPH oxidase, a key mediator of oxidative cardiac damage and remodelling, modulates anthracycline clinical cardiotoxicity. Purpose Single nucleotide polymorphisms (SNPs) of NADPH oxidase genes could lead to interindividual differences in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::252d68a759afe7ff05cc4096e3ef9028
https://doi.org/10.1136/ejhpharm-2016-000875.423
https://doi.org/10.1136/ejhpharm-2016-000875.423
Autor:
A García Robles, PG Kostadinova, C Borrell García, A Albert Marí, JE Megías Vericat, MJ Company Albir, R Sanz Martinez, P Pérez Huertas, E López Briz, JL Poveda Andrés
Publikováno v:
European Journal of Hospital Pharmacy. 23:A242.2-A243
Background Paclitaxel is commonly associated with infusion reactions (IR) with no clear influence of different paclitaxel formulations. Purpose To analyse the number and severity of IR related to administration of different generic formulations of pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e48d4a89b4505e88b1993ffdd198e34
https://doi.org/10.1136/ejhpharm-2016-000875.550
https://doi.org/10.1136/ejhpharm-2016-000875.550
Autor:
Miguel-Angel Sanz, Salvador F. Aliño, David Martínez-Cuadrón, JE Megías Vericat, Federico Moscardó, María José Herrero, Luis Rojas, José Luis Poveda, Virginia Bosó, Pau Montesinos
Publikováno v:
European Journal of Hospital Pharmacy. 22:A133.1-A133
Background Single nucleotide polymorphisms (SNPs) could lead to inter-individual differences in treatment outcomes. Purpose A recent study 1 reported several novel SNPs involved in cytarabine cytotoxicity using a whole-genome approach, which were ass
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dbe20674e2ae1d3a0efafd5fa0b10c99
https://doi.org/10.1136/ejhpharm-2015-000639.321
https://doi.org/10.1136/ejhpharm-2015-000639.321
Autor:
J. Ruiz Ramos, J Reig Aguado, C Borrell García, M.J. Esteban Mensua, J.L. Poveda Andrés, MJ Ausina Ausina, E López Briz, JE Megías Vericat
Publikováno v:
European Journal of Hospital Pharmacy. 20:A155.3-A156
Background Minimization of chemotherapy costs has become a rational goal in today’s economic environment. Purpose To assess the cost savings achieved by optimising vial residues during chemotherapy preparation. Materials and Methods A longitudinal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::af9ea4796da16d07e20b299a61974b93
https://doi.org/10.1136/ejhpharm-2013-000276.430
https://doi.org/10.1136/ejhpharm-2013-000276.430
Autor:
JE Megías Vericat, M.J. Esteban Mensua, J Reig Aguado, E López Briz, C Borrell García, J. Ruiz Ramos, Poveda Jl Andrés
Publikováno v:
European Journal of Hospital Pharmacy. 20:A110.2-A110
Background Panitumumab is a human monoclonal antibody indicated in the treatment of colorectal carcinoma (CRC) that is currently being tested in otolaryngology (ENT) tumours. Recent studies suggest that hypomagnesaemia ( Purpose To review the effecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::55a39f9c0c0bd6adbce5839f842d3f99
https://doi.org/10.1136/ejhpharm-2013-000276.307
https://doi.org/10.1136/ejhpharm-2013-000276.307